Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Endocrine Therapy vs Chemotherapy in Premenopausal HR+ HER2- Breast Cancer
NCT02535221Phase 3Recruiting
- Sponsor
- Peking University
- Start
- Jul 2015
- Primary completion
- Jun 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin and tamoxifen in breast cancer, sponsored by Peking University. Started Jul 2015; status: recruiting.
02
Drugs
goserelintamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02535221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535221.